This article is more than 5 years old. Information may no longer be current.
AGTC, Foundation Fighting Blindness form partnership
Click Here to Manage Email Alerts
The Foundation Fighting Blindness has joined Applied Genetics Technology Corporation in a partnership agreement to advance gene therapy research to treat inherited diseases, the two entities announced in a joint press release.
AGTC will provide grant funding to support the foundation’s My Retina Tracker registry as well as a study intended to identify barriers that prevent patients from participation in genetic testing.
Furthermore, patients included in the registry who have been diagnosed with X-linked retinoschisis, X-linked retinitis pigmentosa or achromatopsia will have the option of undergoing genetic testing to determine their eligibility for one of AGTC’s gene therapy clinical trials.
“AGTC’s support will allow us to bring information about the advancements in treating inherited retinal diseases to more people and in doing so helps us get closer to our goal of bringing hope to people affected by these blinding conditions,” chief development officer for Foundation Fighting Blindness Valerie Navy-Daniels said in the release.
"FFB’s early support of AGTC’s research efforts helped us advance our gene therapy candidates into clinical trials that have the potential to improve the lives of patients,” Sue Washer, AGTC president and CEO, said in the release.